15 Aug 2017 07:00
Two further US patents to be granted
15 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office has issued a notice of allowance for US patent applications 15/589,968 and 15/594,349.
Silence has made the relevant payment of grant fees and normal practice is that the granted patents will now be issued by the US Patent and Trade Mark Office. The allowed claims of both patent applications provide Silence with further protection for its innovative chemical modification technology in the US. Silence
believes these allowed claims are relevant to third party medicines in ongoing clinical trials.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
"The two additional patent applications that have been allowed for grant by the US Patent and Trade Mark Office provide further protection for our US patent estate. With the grant of these, and other recently allowed US patent applications, we will have nine granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio and that such licences could have a material financial effect on Silence."
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
|
|
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.